Reference Library

GLP-1 Resource Hub

34 in-depth reference documents, clinical tools, and topic deep-dives — spanning mechanism, pharmacology, trial evidence, guidelines, and emerging science.

Educational use only. These documents are independent educational resources compiled for learning purposes. They do not constitute clinical guidance, are not endorsed by NICE, NHS, EMA, MHRA, or any regulatory body, and should not replace professional judgement or current SmPC/guideline review.

Interactive Tools

Clinical data visualisation

Interactive Tool

Advanced GLP-1 RA Clinical Intelligence Suite

Patient parameter input → radar chart drug comparison across HbA1c, weight, CV, renal, GI tolerability axes. Titration predictor with RCT vs real-world data. Drug selection engine across 8 clinical scenarios.

Clinical Reference

GLP-1 RA drug comparison

GLP-1 RA Drug Compendium — Clinical Quick Reference

Complete drug profiles: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide. HbA1c reductions, weight outcomes, CV trial results, dosing, half-lives, renal dosing adjustments.

GLP-1 RA Safety & Side Effects Reference

GI incidence data (nausea 15–45%), pancreatitis, gallbladder disease, MTC risk, AKI, retinopathy. Contraindication checklist. Monitoring protocols. Management strategies per adverse effect.

Patient selection algorithm

GLP-1 RA in Special Populations

CKD, pregnancy (contraindication + washout periods), frailty/elderly, hepatic impairment, heart failure, perioperative management, T1DM, PCOS. Evidence and SmPC-based guidance per population.

Upper GI anatomy

GLP-1 RA Gastrointestinal Side Effects

Mechanism of GI effects (gastric emptying delay, central nausea pathways), time course, comparative incidence across agents, dietary management strategies, titration-based mitigation.

Neuroendocrine axis

GLP-1 RA Thyroid Safety

MTC/MEN2 black box warning — rodent vs human evidence, C-cell biology, calcitonin monitoring. Benign thyroid effects. Differentiation from other thyroid pathology. Clinical counselling framework.

Metabolic panel

GLP-1 RA & Hypertriglyceridaemia

GLP-1 RA effects on triglycerides (↓15–25% via ↓hepatic VLDL, ↑lipoprotein lipase, ↓chylomicron production). Hypertriglyceridaemia-induced pancreatitis — treatment protocol and role of GLP-1 RA.

Mechanism & Physiology

GLP-1 receptor structure

GLP-1 Physiology — Receptor Biology & Signalling

GLP-1 secretion from intestinal L-cells, DPP-4 degradation (t½ 1–2 min), receptor distribution across organ systems, Gαs/cAMP/PKA pathway, EPAC2, K-ATP channel mechanism in detail.

Cardioprotective signalling

GLP-1 RA Cardioprotection — Mechanisms Deep Dive

Direct cardiac effects (GLP-1R on cardiomyocytes → PI3K/Akt, ↓apoptosis, ↑glucose uptake), vascular (↑eNOS, ↓NF-κB, ↓atherosclerotic plaque), blood pressure (2–5 mmHg systolic), lipids.

Mesolimbic GLP-1 pathways

GLP-1 RA Neuroprotection & Brain Effects

BBB crossing, hypothalamic arcuate nucleus (POMC/CART ↑, NPY/AgRP ↓), mesolimbic dopamine/reward pathways, ↓neuroinflammation (NF-κB), ↑BDNF, EVOKE trial in Alzheimer's disease.

FLOW trial renal outcomes

GLP-1 RA Renal Protection

FLOW trial: semaglutide 1.0mg, N=3,533, 24% slower eGFR decline, 22% ESKD reduction. Mechanism: NHE3 inhibition, natriuresis, ↓intraglomerular pressure, albuminuria reduction (UACR −20–30%), anti-inflammatory effects.

HFpEF semaglutide mechanism

GLP-1 RA in Heart Failure

STEP-HFpEF trial: semaglutide in HFpEF with obesity — KCCQ improvement, weight loss, NT-proBNP reduction. Differentiation from SGLT2i in HFrEF. Patient selection and prescribing considerations.

Evolutionary history of GLP-1 agonists

History of GLP-1 Receptor Agonists

Discovery of GLP-1 in the 1980s, Gila monster (exendin-4), first DPP-4-resistant analogues, exenatide approval (2005), liraglutide (2009), CVOT era, semaglutide era, and the obesity revolution.

Disease Areas & Applications

SURMOUNT weight loss programme

GLP-1 RA in Obesity — Evidence & Access

STEP 1–5 (semaglutide), SURMOUNT-1 (tirzepatide −22.5%), NICE TA875 (Wegovy), NICE TA1026 (Mounjaro) criteria, NHS specialist weight management services, re-prescribing evidence, weight regain on cessation.

Hepatic lobule semaglutide effects

GLP-1 RA in Liver Disease (MASLD/MASH)

Semaglutide NASH trial: ≥1-stage fibrosis improvement in 43%. Hepatic fat reduction 30–40% (↓de novo lipogenesis, ↓SREBP-1c). Anti-inflammatory (↓Kupffer cell). Survodutide Phase 2: MASH resolution 68%.

Hippocampal neuron GLP-1 effects

GLP-1 RA in Addiction & Substance Use

Mesolimbic dopamine modulation reducing cravings — alcohol, nicotine, opioid use disorder. Epidemiological signals from insurance databases. Phase 2 trial data and proposed CNS mechanism.

Female reproductive endocrinology

GLP-1 RA in PCOS & Fertility

Weight loss improving menstrual regularity, HOMA-IR reduction, androgen levels, ovulation restoration. Contraception requirement (GLP-1 RA in pregnancy — absolute contraindication). Fertility treatment considerations.

Neurohormonal dual effects

GLP-1 RA in Sleep Apnoea

SURMOUNT-OSA: tirzepatide reduced AHI (apnoea-hypopnea index) by 55% vs 5% placebo in obesity-associated OSA. Weight loss mechanism, upper airway adipose reduction, direct GLP-1R effects on respiratory control.

Bone microarchitecture

GLP-1 RA & Bone Health

GLP-1 receptors on osteoblasts — anabolic signals. Concern about rapid weight loss and lean mass reduction on bone density. DXA monitoring consideration. Fracture data from long-term obesity trials.

Skeletal muscle GLP-1 effects

GLP-1 RA & Muscle Research

Lean mass reduction during weight loss: ~25–35% of total weight lost is lean mass. SURMOUNT data on muscle preservation. Importance of resistance exercise and protein intake. Sarcopenia risk in older adults.

GLP-1 organ effects

GLP-1 RA & Eye Health

Diabetic retinopathy risk with rapid HbA1c lowering (SUSTAIN-6 signal: HR 1.76 for retinopathy complications). Early worsening phenomenon — mechanism and monitoring. Longer-term data from LEADER and SELECT.

Adipose tissue landscape

GLP-1 RA & Skin/Hair Effects

Telogen effluvium (hair loss) associated with rapid weight loss — mechanism, time course, and resolution. Skin laxity after major weight loss. GLP-1 RA-specific vs weight-loss-related dermatological effects.

Guidelines & Regulatory

NICE TA1026 Mounjaro

NICE 2026 GLP-1 RA Guidelines Summary

NG28, TA875 (Wegovy), TA1026 (Mounjaro), NG238 (Obesity). Eligibility criteria, prescribing conditions, stopping rules, monitoring requirements, and NHS access pathway overview.

ADA 2026 unified guidance

ADA 2026 GLP-1 RA Position Statement

ADA/EASD 2024 consensus updates for 2026: GLP-1 RA as first-line in established ASCVD or high CV risk, weight loss priority, CKD. Treatment algorithm, individualisation framework, and deintensification guidance.

Clinical decision framework

WHO GLP-1 RA Guidelines 2025

Global perspective on GLP-1 RA access, essential medicines list considerations, low- and middle-income country implementation, cost-effectiveness evidence, and WHO essential diabetes medicines framework.

NICE health technology assessment

GLP-1 RA Regulatory Updates

MHRA, EMA, FDA regulatory decisions. New indications (CKD, CV, sleep apnoea). Label changes, REMS updates, SmPC revisions, post-marketing surveillance findings, Yellow Card signals and responses.

Emerging Science & Pipeline

Next-generation GLP-1 pipeline timeline

Next-Generation GLP-1 Agents — 2026 Clinical Reference

Retatrutide (triple GLP-1/GIP/glucagon, 24.2% WL, TRIUMPH Phase 3), Orforglipron (oral non-peptide, 14.7%), CagriSema (22.7%), Survodutide (MASH), Pemvidutide. Phase 3 status, mechanism, expected timelines.

Mechanism Visualisations

GLP-1 signalling pathways

GLP-1 Mechanism Visualisation

Animated/interactive visualisation of GLP-1 receptor signalling — pancreatic, cardiovascular, neurological, and renal pathways rendered visually for teaching and learning.

Pancreatitis safety data

Pancreatitis Risk Visualisation

Visual reference for understanding the relationship between GLP-1 RAs and pancreatitis — incidence data, risk factors, mechanism hypotheses, and clinical decision framework.